MPN Chronicles Podcast by David Wallace I started 2020 with a goal to lose weight before the pandemic reared its ugly head. I changed the way I was eating, lobbied my hematologist for a change in PV meds (no more Rux/Peg combo, just Pegasys) and I started walking again. When Covid hit, I decided to […]
Best Mobile Apps for MPN Cancer Patients
by Deb Wesloh & Lou Ann Donovan Apps can help Manage your Life with Cancer Mobile applications for smartphones and tablets, also known as apps, are becoming a rising resource to help people with cancer manage their day-to-day life. Apps are also an easy resource for family members to stay informed and provide support for […]
Differential cytokine network profile in Polycythemia Vera and Secondary Polycythemia
Authors: Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Maria Gabriela Berzoti-Coelho, Raquel Tognon, Natalia de Souza Nunes, Belinda Simões, Ítalo Sousa Pereira, Daniela Carlos, Lucia Helena Faccioli, Lorena Lobo de Figueiredo-Pontes, Fabiani Gai Frantz & Fabíola Attié de Castro Scientific Reports volume 10, Article number: 7032 (2020) Abstract Polycythemia vera (PV) is a clonal disorder resulting from neoplastic transformation of hematopoietic stem cells, while secondary polycythemia (SP) is a disease characterized by increased absolute […]
Immunotherapy in Myeloproliferative Diseases
by Lukas M. Braun 1,2 and Robert Zeiser 1,3,4,5,* 1 Department of Medicine I, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; lukas.braun@uniklinik-freiburg.de 2 Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany 3 German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 4 […]
PTG-300 Hepcidin Mimetic Receives FDA Orphan Drug Designation for Treatment of Polycythemia Vera
NEWARK, Calif., June 17, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis. “Receiving […]
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 42
- Next Page »
